Formulary Focus: <em>Cosentyx</em> Navigating Tightly Managed Psoriasis Market

Formulary Focus: Cosentyx Navigating Tightly Managed Psoriasis Market

01 Jun 2015

Payers’ prior authorization and step therapy requirements may delay broad access to Novartis’ Cosentyx until after competition arrives in 2016 from Lilly’s IL-17 inhibitor and possibly from a biosimilar to Humira.

Access challenges may undercut Novartis AG’s first-mover advantage as it seeks to establish itsnew plaque psoriasis treatment Cosentyx (secukinumab) in a tightly controlled reimbursement environment.

“The key going forward [for Cosentyx] is going to be gaining access, which we’re working through,” Novartis Pharmaceuticals Division Head...